FRM
PVLA

Fox Run Management’s Palvella Therapeutics PVLA Stock Holding History

Fox Run Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-185
Closed -$77K – 738
2021
Q3 		$77K Buy
+185
New +$64.4K 0.05% 442
2018
Q3 		– Sell
-306
Closed -$124K – 863
2018
Q2 		$124K Buy
+306
New +$146K 0.04% 621

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fox Run Management's PVLA Position: Q4 2021 in Review

Fox Run Management sold out of Palvella Therapeutics (PVLA) in Q4 2021, closing a stake of 185 shares — an estimated $77K sold.

Fox Run Management first reported a position in PVLA in Q2 2018 and held it in 2 quarters. The position peaked at $124K in Q2 2018. 81 funds tracked by Wall St. Rank hold PVLA as of Q4 2021.

  • Fox Run Management reported no remaining Palvella Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Fox Run Management sold 185 Palvella Therapeutics shares in Q4 2021, an estimated $77K.
  • Fox Run Management first reported a position in Palvella Therapeutics in Q2 2018 and held it in 2 quarters.
  • Fox Run Management's Palvella Therapeutics position peaked at $124K in Q2 2018.
  • 81 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2021.

Based on Fox Run Management's 13F filing for Q4 2021, filed 9 Feb 2022.